Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Payment for prescription drugs

Austria Does not affect 80% of the population. A percentage rate of co-payment for health care is applied to the rest, unless exempted for reasons of low income Combination of co-payment and percentage rate (with exemptions). The scheme of direct payments by the patient is limited to the first 28 days of hospitalization Co-payment for prescription drugs. Drugs not prescribed by health professionals are excluded... [Pg.8]

This shift toward more third-party payment for prescription drugs has had a significant impact on pharmacy management. Pharmacies determine what price they want to charge private-pay patients, but as will be discussed in more detail later in this chapter, third... [Pg.267]

Figure 16-1. U.S. Prescription Drug Expenditures by Source of Payment, 1990-2005. Source Data were obtained from the Centers for Medicare and Madicaid Service at http //www.cms.hhs.gov/NationalHealthExpendData/ Note PT OOP is direct spending by consumers for prescriptions drugs. It includes prescriptions not covered by a third party and patient cost-sharing for third parly prescriptions. Figure 16-1. U.S. Prescription Drug Expenditures by Source of Payment, 1990-2005. Source Data were obtained from the Centers for Medicare and Madicaid Service at http //www.cms.hhs.gov/NationalHealthExpendData/ Note PT OOP is direct spending by consumers for prescriptions drugs. It includes prescriptions not covered by a third party and patient cost-sharing for third parly prescriptions.
OTA reviewed recent trends in payment methods for prescription drugs in five countries Australia, Canada, France, Japan, and the United Kingdom. To a greater or lesser extent in each of these countries, drug payment policy is governed by two potentially conflicting objectives to minimize health insurance prescription drug costs and to help the country s domestic pharmaceutical industry. Payment policies represent a blend between these objectives. [Pg.250]

Australia s domestic pharmaceutical industry is very small, and the country represents a small proportion of the world market for prescription drugs.31 Consequently, Australia has not had a major economic stake in promoting pharmaceutical R D. Instead, the main objective of Australia s pharmaceutical payment policies has been to minimize the cost of drugs, both to the government and to its citizens. Recently, though, the government has made efforts to promote the... [Pg.250]

Finally, consumers, or individual health plan members, represent another payer group within managed care. Consumers pay for healthcare through health plan premiums, deductibles, and benefit-specific co-payments, including prescription drug co-payments. To address consumer needs, as well as to expand market share, many pharmaceutical companies have invested significant... [Pg.520]

Sweden Co-payment, with maximum levels of sharing in health service bills, with the exception of hospital in-patient bills Per diem co-payment for in-patient services. Co-payment for therapeutic referrals Co-payment for the first drug prescribed, with significantly lower co-payments for subsequent prescriptions. RP system for medicines with generic equivalents... [Pg.10]

More recently, large databases have been used to estimate the effect of drug co-payment in the USA under different insurance schemes.10 The conclusion reached is that there is a significant interaction effect between the behaviour of demand and prescriber incentives. Thus, larger prescription drug copayments are associated with lower expenditure when the doctor does not share the financial risk of the cost of the drugs (that is, practises in an independent practice association) but this effect is barely perceived in managed care models in which the doctor has incentives for cost containment. [Pg.139]

Safe Medical Device Amendments, requiring more extensive testing of devices. 1992 Prescription Drug User Fee Act. Established the payment of fees for the filing of applications (e.g., IND, NDA, PLA, etc.)... [Pg.33]

The legislation went into effect on December 10, 2005, with several provisions for enforcement. Any person in the District of Columbia who is adversely affected by the excessive prices could file suit. Remedies included an injunction to stop sales of the prescription drug, and payment of fines, damages, attorneys fees, or court costs. [Pg.99]


See other pages where Payment for prescription drugs is mentioned: [Pg.22]    [Pg.33]    [Pg.237]    [Pg.239]    [Pg.241]    [Pg.243]    [Pg.245]    [Pg.247]    [Pg.249]    [Pg.251]    [Pg.253]    [Pg.255]    [Pg.257]    [Pg.259]    [Pg.261]    [Pg.263]    [Pg.22]    [Pg.33]    [Pg.237]    [Pg.239]    [Pg.241]    [Pg.243]    [Pg.245]    [Pg.247]    [Pg.249]    [Pg.251]    [Pg.253]    [Pg.255]    [Pg.257]    [Pg.259]    [Pg.261]    [Pg.263]    [Pg.799]    [Pg.92]    [Pg.127]    [Pg.267]    [Pg.281]    [Pg.558]    [Pg.325]    [Pg.438]    [Pg.735]    [Pg.45]    [Pg.31]    [Pg.238]    [Pg.797]    [Pg.47]    [Pg.33]    [Pg.33]    [Pg.156]    [Pg.157]    [Pg.161]    [Pg.61]    [Pg.66]   


SEARCH



Payment

© 2024 chempedia.info